Viatris (VTRS) - Stock Price & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US92556V1061

Prescription drugs, Generic drugs, Biosimilars, Active pharmaceutical ingredients

Viatris Inc. is a global healthcare company that operates in four main segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers a wide range of products, including prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs).

Viatris Inc.'s product portfolio covers various therapeutic areas, such as noncommunicable and infectious diseases. Its biosimilars are used to treat conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. The company also provides APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas.

In addition to its products, Viatris Inc. offers support services to help patients better manage their health. These services include diagnostic clinics, educational seminars, and digital tools. The company distributes its products to a wide range of customers, including retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions.

Viatris Inc.'s products are available in various forms, including oral solid doses, injectables, complex dosage forms, and APIs. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies.

The company sells its products under various brand names, including Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. Viatris Inc. has collaboration and licensing agreements with other companies, such as Revance Therapeutics, Inc. and Momenta Pharmaceuticals, Inc.

Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania. The company's website can be found at

With a long history and a strong presence in the global healthcare market, Viatris Inc. is a leading player in the pharmaceutical industry. Its diverse product portfolio, extensive distribution network, and commitment to patient support services make it a significant player in the healthcare sector.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Viatris (VTRS) - Stock Price & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for Viatris (VTRS) - Stock Price & Dividends

VTRS Stock Overview

Market Cap in USD 14,062m
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
GiC SubIndustry Pharmaceuticals
TER 0.00%
IPO / Inception 2020-11-16

VTRS Stock Ratings

Growth 5y -2.54
Fundamental 6.51
Dividend 4.68
Rel. Performance vs Sector 0.95
Analysts 3.10/5
Fair Price Momentum 11.83 USD
Fair Price DCF 39.48 USD

VTRS Dividends

Yield 12m 4.34%
Yield on Cost 5y 2.83%
Dividends CAGR 5y 2.94%
Payout Consistency 56.1%

VTRS Growth Ratios

Growth 12m 22.42%
Growth Correlation 12m 44%
Growth Correlation 3m -70%
CAGR 5y -8.18%
CAGR/Mean DD 5y -0.22
Sharpe Ratio 12m 0.65
Alpha vs SP500 12m 0.73
Beta vs SP500 5y weekly 0.71
ValueRay RSI 17.97
Volatility GJR Garch 1y 32.97%
Price / SMA 50 -4.57%
Price / SMA 200 3.17%
Current Volume 11115k
Average Volume 20d 9038k

External Links for VTRS Stock

Wall Street JournalBenzingaYahoo Finance
Fund Manager Positions
What is the price of VTRS stocks?
As of May 21, 2024, the stock is trading at USD 11.07 with a total of 11,114,950 shares traded.
Over the past week, the price has changed by -2.55%, over one month by -1.60%, over three months by -15.57% and over the past year by +24.26%.
What are the forecast for VTRS stock price target?
According to ValueRays Forecast Model, VTRS Viatris will be worth about 12.8 in May 2025. The stock is currently trading at 11.07. This means that the stock has a potential upside of +15.36%.
Issuer Forecast Upside
Wallstreet Target Price 15.7 41.9
Analysts Target Price 14.8 33.5
ValueRay Target Price 12.8 15.4